Silence Therapeutics plc (OTCMKTS:SLNCF) Sees Significant Increase in Short Interest

Silence Therapeutics plc (OTCMKTS:SLNCF) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 2,600 shares, an increase of 333.3% from the May 31st total of 600 shares. Based on an average trading volume of 700 shares, the days-to-cover ratio is currently 3.7 days.

Silence Therapeutics Price Performance

Shares of OTCMKTS SLNCF remained flat at $6.50 during mid-day trading on Thursday. The company had a trading volume of 1,500 shares, compared to its average volume of 1,128. Silence Therapeutics has a 12 month low of $0.60 and a 12 month high of $10.90. The firm’s fifty day simple moving average is $7.30 and its 200 day simple moving average is $5.17.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.